ClinicalTrials.gg
CompletedNCT02452632Updated Nov 12, 2024

A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin

A Phase 3 interventional study of ASP1941 and Placebo in Type 2 Diabetes Mellitus, sponsored by Astellas Pharma Korea, Inc.. Completed at 22 sites in Korea, Republic of. Open to participants aged 19 Years to 74 Years. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by Astellas Pharma Korea, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
19 Years to 74 Years
Sex
All
01

Study summary

The purpose of this study is to compare the efficacy and safety of ASP1941 50mg once daily in combination with metformin and sitagliptin against placebo in combination with metformin and sitagliptin over a 24 week treatment period in subjects with type 2 diabetes mellitus with inadequate glycemic control on metformin and sitagliptin.

02

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • ASP1941
  • Type 2 diabetes mellitus
03

In context

Diabetes Mellitus, Type 2

10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.

This study's enrollment of 143 is above the median of 80 across 8,350 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Astellas Pharma Korea, Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has been diagnosed with type 2 diabetes mellitus.
  • Subject has an value between 7.0% and 10.5 % at visit 1.
  • Subject shows FPG (Fasting Plasma Glucose) value is less than 270mg/dL.
  • Subject shows a of 20.0 to 45.0 kg/m2.
  • Subject is on stable diet and exercise program at least 8 weeks prior to study participation.
  • female or surgically sterile female or agree not to become pregnant.

Exclusion criteria

Exclusion Criteria:

  • Subject has type 1 diabetes mellitus.
  • Subject has proliferative diabetic retinopathy.
  • Subject has a history of renal disease(s) such as renovascular occlusive disease, nephrectomy, or renal transplant.
  • Subject has significant dysuria caused by a neurogenic bladder or a benign prostatic hypertrophy etc.
  • Subject has a symptomatic urinary tract infection or genital infection.
  • Subject has chronic disease(s) that require the continuous use of systemic or .
  • Subject has cardiovascular disease or cerebrovascular disease that may affect the administration of ASP1941 or its safety assessment in the opinion of the investigator or sub-investigator.
  • Subject has uncontrollable psychiatric disorder(s) with medication.
  • Male subject is not willing to use appropriate during the study.
  • Subject has severe infection, serious trauma, or perioperative subject.
  • Subject has a malignant tumor or has a history of malignant tumor.
  • Subject has severe gastrointestinal disease, or history of operation for serious gastrointestinal disease.
  • Subject has diabetic ketoacidosis.
  • Subject has lactic acidosis or has history of lactic acidosis.
  • Subject has hepatitis or is a carrier of surface antigen (HBsAg), virus (HCV) antibody, or is positive for -1 and/or HIV-2.
  • Subject has a history of thyroid dysfunction and acute pancreatitis.
  • Subject is on weight-loss program or weight-loss medication (e.g. orlistat, phentermine/topiramate, lorcaserin) within 12 weeks of study participation.
  • Subject has a history of serious cardiac diseases ( Class III to IV), congestive heart failure, arrhythmia in need of medical treatment.
  • Subject has a history of cerebrovascular attack, unstable angina, myocardial infarction, angioplasty, within 52 weeks (364 days) of study participation.
  • Subject has uncontrollable severe hypertension, i.e., systolic blood pressure of higher than 180 mmHg or diastolic blood pressure of higher than 110mmHg measured in a sitting position after a 5-minute rest.
  • Subject has following or ALT value:

    • AST: Male > 100 U/L, Female > 80 U/L
    • ALT: Male > 102.5 U/L, Female > 82.5 U/L
  • Subject has following serum creatinine value:

    • Creatinine: Male > 1.3 mg/dL, Female > 1.2 mg/dL
  • Subject has estimated values, of \< 60 mL/min/1.73m2.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    ASP1941 group

    once daily over a 24 week treatment

    Drug: ASP1941

  • Placebo comparator
    Placebo group

    once daily over a 24 week treatment

    Drug: Placebo

Interventions

  • oral

    Also known as: ipragliflozin, Suglat

  • DrugPlacebo

    oral

06

What researchers measure

Primary outcomes

  1. Change from baseline in HbA1c at the end of treatment

    Time frame: at 24 weeks

Secondary outcomes

  1. Change from baseline in Fasting plasma glucose at the end of treatment

    Time frame: at 24 weeks

  2. Change from baseline in Fasting serum insulin at the end of treatment

    Time frame: at 24 weeks

  3. Change from baseline in Body weight at the end of treatment

    Time frame: at 24 weeks

  4. Change from baseline in Waist circumference at the end of treatment

    Time frame: at 24 weeks

  5. Safety assessed by development of adverse events, vital signs, laboratory tests, and 12-lead ECG

    ECG: Electrocardiogram

    Time frame: up to 24 weeks

  6. Number of subjects achieving the target HbA1c(<6.5% and <7.0%) at each visit

    Time frame: at 4, 8, 12, 16 and 24 weeks

  7. Percentage of subjects achieving the target HbA1c(<6.5% and <7.0%) at each visit

    Time frame: at 4, 8, 12, 16 and 24 weeks

07

Study locations

22 sites
  • Site KR00002
    Busan, Korea, Republic of
  • Site KR00003
    Busan, Korea, Republic of
  • Site KR00007
    Daegu, Korea, Republic of
  • Site KR00011
    Daegu, Korea, Republic of
  • Site KR00019
    Dong Gu Gwangju, Korea, Republic of
  • Site KR00008
    Gangwon-do, Korea, Republic of
  • Site KR00018
    Gyeonggi-do, Korea, Republic of
  • Site KR00022
    Gyeonggi-do, Korea, Republic of
  • Site KR00014
    Incheon, Korea, Republic of
  • Site KR00020
    Jeollabuk-do, Korea, Republic of
  • Site KR00021
    Kyungsangnam-do, Korea, Republic of
  • Site KR00001
    Seoul, Korea, Republic of
  • Site KR00004
    Seoul, Korea, Republic of
  • Site KR00005
    Seoul, Korea, Republic of
  • Site KR00006
    Seoul, Korea, Republic of
  • Site KR00009
    Seoul, Korea, Republic of
  • Site KR00010
    Seoul, Korea, Republic of
  • Site KR00012
    Seoul, Korea, Republic of
  • Site KR00013
    Seoul, Korea, Republic of
  • Site KR00016
    Seoul, Korea, Republic of
  • Site KR00017
    Seoul, Korea, Republic of
  • Site KR00015
    Suwon, Korea, Republic of
08

References and documents

Publications

  • Kashiwagi A, Shestakova MV, Ito Y, Noguchi M, Wilpshaar W, Yoshida S, Wilding JPH. Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. Diabetes Ther. 2019 Dec;10(6):2201-2217. doi: 10.1007/s13300-019-00699-8. Epub 2019 Oct 12. PubMed 31606880 ↗

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Jan 2017, 18 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2015
First posted
May 22, 2015
StartActual
Jun 22, 2015
Primary completionActual
Jan 5, 2017
CompletionActual
Jan 5, 2017
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02452632
Responsible party
Sponsor
First posted
May 22, 2015
Start date
Jun 22, 2015
Primary completion
Jan 5, 2017
Completion
Jan 5, 2017
Last update
Nov 12, 2024

Study contacts

Medical Director
study director · Astellas Pharma Korea, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ipragliflozin

Start the discussion